{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-22-018894","form_type":"8-K","ticker":"PBYI","cik":"0001401667","company_name":"PUMA BIOTECHNOLOGY, INC.","filed_at":"2022-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.619234+00:00","generated_at":"2026-06-24T03:52:46.488239+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Puma Biotech swings to Q2 profit of $0.21/sh; NERLYNX revenue up 5%","bullets":["GAAP net income $9.4M ($0.21 per share) vs net loss of $5.1M ($0.13 loss) in Q2 2021.","Total revenue $59.5M ($51.3M product, $8.2M royalties) vs $53.4M in Q2 2021.","Operating expenses fell sharply: SG&A $20.6M (down 48%), R&D $11.9M (down 36%).","Cash and securities $60.8M at June 30, down from $82.1M at Dec 31, 2021.","Management guides for FDA meetings on registration pathways for neratinib in H2 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-22-018894","json":"https://secwatch.observer/filing/0001437749-22-018894.json","markdown":"https://secwatch.observer/filing/0001437749-22-018894.md","text":"https://secwatch.observer/filing/0001437749-22-018894.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401667/000143774922018894/0001437749-22-018894-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401667/000143774922018894/pbyi20220802_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T03:52:46.488239+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}